肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展

doi:10.11904/j.issn.1002-3070.2022.06.006

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (6): 520-525.doi: 10.11904/j.issn.1002-3070.2022.06.006

• 消化道肿瘤免疫治疗专题 • 上一篇下一篇

肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展

程思远^1,2, 韩子翰¹, 郭晓欢³, 沈琳¹（综述）, 彭智¹（审校）

1.北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科,恶性肿瘤发病机制及转化研究教育部重点实验室(北京 100142);
2.北京大学第三医院肿瘤化疗与放射病科;
3.清华大学医学院免疫学研究所

收稿日期:2022-01-10 修回日期:2022-08-10 出版日期:2022-12-28 发布日期:2023-01-06
通讯作者: 彭智,E-mail:zhipeng@bjmu.edu.cn
作者简介:程思远,男,(1993-),博士,住院医师,从事消化道肿瘤精准治疗的研究
基金资助:
国家自然科学基金面上项目(编号:82272764);北京市自然科学基金重点项目(编号:Z210015)

Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions

CHENG Siyuan^1,2, HAN Zihan¹, GUO Xiaohuan³, SHEN Lin¹, PENG Zhi¹

1. Department of Gastrointestinal Oncology,Peking University Cancer Hospital & Institute,Key laboratory of Carcinogenesis and Translational Research(Ministry of Education),Beijing 100142,China;
2. Department of Medical Oncology and Radiation Sickness,Peking University Third Hospital;
3. Institute for Immunology,School of Medicine,Tsinghua University

Received:2022-01-10 Revised:2022-08-10 Online:2022-12-28 Published:2023-01-06

摘要/Abstract

摘要： 肠道菌群是寄生于肠道内微生物的总称。肠道菌群受到宿主饮食和药物等多种因素影响,同时,肠道菌群也可以参与调控宿主免疫状态。目前,已有一些研究证实了肠道菌群与抗肿瘤免疫治疗疗效及不良反应具有相关性,且调节肠道菌群可以提升免疫治疗疗效,但是具体的机制尚不清楚。本文对肠道菌群与肿瘤免疫治疗现有的研究进展及不足进行了系统综述。

关键词: 肠道菌群, 免疫治疗, 粪菌移植

Abstract: Gut microbiota is the general term for microorganisms that live in the intestine.The microbiota is affected by many factors such as the host's diet and drugs.At the same time, the microbiota can also participate in the regulation of the host's immune status.At present, some studies have confirmed that the intestinal flora is related to the efficacy and adverse reactions of anti-tumor immunotherapy, and regulating the flora can improve the efficacy of immunotherapy, but the specific mechanism is still unclear.This article systematically reviews the current research progress and shortcomings of gut microbiota and tumor immunotherapy.

Key words: Intestinal flora, Immunotherapy, Fecal microbiota transplantation

中图分类号:

程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.

CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions[J]. Journal of Practical Oncology, 2022, 36(6): 520-525.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/520

参考文献

1 Xu K,Jiang B.Analysis of mucosa-associated microbiota in colorectal cancer[J].Med Sci Monit,2017,23:4422-4430.
2 Qi YF,Sun JN,Ren LF,et al.Intestinal microbiota is altered in patients with gastric cancer from Shanxi province,china[J].Dig Dis Sci,2019,64(5):1193-1203.
3 Peng Z,Cheng S,Kou Y,et al.The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer[J].Cancer Immunol Res,2020,8(10):1251-1261.
4 Routy B,Le Chatelier E,Derosa L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science,2018,359(6371):91-97.
5 Derosa L,Routy B,Thomas AM,et al.Intestinal akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer[J].Nat Med,2022,28(2):315-324.
6 Lee KA,Thomas AM,Bolte LA,et al.Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma[J].Nat Med,2022,28(3):535-544.
7 McCulloch JA,Davar D,Rodrigues RR,et al.Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1[J].Nat Med,2022,28(3):545-556.
8 Kespohl M,Vachharajani N,Luu M,et al.The microbial metabolite butyrate induces expression of Th1-associated factors in CD4(+)T cells[J].Front Immunol,2017,8:1036.
9 Luu M,Weigand K,Wedi F,et al.Regulation of the effector function of CD8(+)T cells by gut microbiota-derived metabolite butyrate[J].Sci Rep,2018,8(1):14430.
10 Bachem A,Makhlouf C,Binger KJ,et al.Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+)T cells[J].Immunity,2019,51(2):285-297.
11 He Y,Fu L,Li Y,et al.Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+)T cell immunity[J].Cell Metab,2021,33(5):988-1000.
12 Nomura M,Nagatomo R,Doi K,et al.Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors[J].JAMA Netw Open,2020,3(4):e202895.
13 Coutzac C,Jouniaux JM,Paci A,et al.Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer[J].Nat Commun,2020,11(1):2168.
14 Mager LF,Burkhard R,Pett N,et al.Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J].Science,2020,369(6510):1481-1489.
15 Vernocchi P,Gili T,Conte F,et al.Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer[J].Int J Mol Sci,2020,21(22):8730.
16 Gopalakrishnan V,Spencer CN,Nezi L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J].Science,2018,359(6371):97-103.
17 Matson V,Fessler J,Bao R,et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J].Science,2018,359(6371):104-108.
18 Jin Y,Dong H,Xia L,et al.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with nsclc[J].J Thorac Oncol,2019,14(8):1378-1389.
19 Zheng Y,Wang T,Tu X,et al.Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J].J Immunother Cancer,2019,7(1):193.
20 Usyk M,Pandey A,Hayes RB,et al.Bacteroides vulgatus and bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma[J].Genome Med,2021,13(1):160.
21 Chau J,Yadav M,Liu B,et al.Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer[J].BMC Cancer,2021,21(1):808.
22 Liu W,Ma F,Sun B,et al.Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors,a real-world study[J].Front Immunol,2021,12:756872.
23 Tan B,Chen MJ,Guo Q,et al.Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events[J].Thorac Cancer,2021,12(12):1814-1823.
24 Chaput N,Lepage P,Coutzac C,et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J].Ann Oncol,2017,28(6):1368-1379.
25 Andrews MC,Duong CPM,Gopalakrishnan V,et al.Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade[J].Nat Med,2021,27(8):1432-1441.
26 Feuerstadt P,Louie TJ,Lashner B,et al.SER-109,an oral microbiome therapy for recurrent clostridioides difficile infection[J].N Engl J Med,2022,386(3):220-229.
27 Tomita Y,Ikeda T,Sakata S,et al.Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer[J].Cancer Immunol Res,2020,8(10):1236-1242.
28 Dizman N,Meza L,Bergerot P,et al.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma:a randomized phase 1 trial[J].Nat Med,2022.28(4):704-712.
29 Baruch EN,Youngster I,Ben-Betzalel G,et al.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients[J].Science,2021,371(6529):602-609.
30 Davar D,Dzutsev A K,McCulloch J A,et al.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J].Science,2021,371(6529):595-602.
31 Ramakrishna C,Corleto J,Ruegger PM,et al.Dominant role of the gut microbiota in chemotherapy induced neuropathic pain[J].Sci Rep,2019,9(1):20324.
32 Derosa L,Routy B,Fidelle M,et al.Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients[J].Eur Urol,2020,78(2):195-206.
33 Lv J,Jia Y,Li J,et al.Gegen qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment[J].Cell Death Dis,2019,10(6):415.

[1]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[2]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[3]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[4]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[5]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[6]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[7]	陈亚丽, 刘婷, 陈娟, 杜秋静. 癌症患者围术期肠道菌群与神经精神症状关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 468-471.
[8]	童曼琳, 尚茹茹, 刘晓红. PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 278-282.
[9]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[10]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[11]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[12]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[13]	王恒敏, 赵琦, 吴华星. 粪便菌群移植在癌症治疗中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 468-471.
[14]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[15]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.

肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展

Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价